Rasonque (daraxonrasib), an oral RAS(ON) multiselective inhibitor, was approved by the U.S. Food and Drug Administration (FDA) on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval is supported by the randomized phase 3 RASolute 302 trial of 500 patients, published in The New England Journal of Medicine, in which daraxonrasib extended median overall survival to 13.2 months compared with 6.7 months with chemotherapy.
The approval introduces the first RAS-targeted therapy for pancreatic cancer
Daraxonrasib is a once-daily oral drug designed to inhibit active RAS proteins, a signaling family that drives tumor growth in most pancreatic ductal adenocarcinomas (PDAC). More than 90% of PDAC tumors carry oncogenic RAS mutations, most commonly in KRAS. The drug forms a three-part complex with RAS and cyclophilin A, preventing active RAS from signaling downstream pathways that support cancer-cell growth and survival.
The FDA indication does not require a specific RAS biomarker. It covers adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment, as well as patients who are not candidates for multiagent systemic therapy. That distinguishes daraxonrasib from narrower biomarker-defined targeted cancer therapies that are approved only for tumors carrying a particular mutation.
RASolute 302 nearly doubled median overall survival
RASolute 302 was an international, open-label, randomized phase 3 trial that enrolled 500 adults with previously treated metastatic PDAC. Patients were randomly assigned to daraxonrasib or investigator-selected chemotherapy. Of the 500 participants, 248 received daraxonrasib and 252 received chemotherapy; 91.8% had tumors with RAS G12 mutations.
The dual primary endpoints were overall survival and progression-free survival (PFS) in the RAS G12 population. Key secondary endpoints included the same outcomes in the overall study population, which included patients with RAS G12, G13, or Q61 mutations and patients in whom no RAS mutation was identified.
In the overall population, median overall survival was 13.2 months with daraxonrasib and 6.7 months with chemotherapy, corresponding to a hazard ratio for death of 0.40 (P<0.001). Median PFS was 7.2 months versus 3.6 months, with a hazard ratio of 0.49 (P<0.001). The objective response rate was 31.6% with daraxonrasib and 11.2% with chemotherapy.
Results were similarly strong in the prespecified RAS G12 population. Median overall survival was 13.2 months with daraxonrasib and 6.6 months with chemotherapy, again with a hazard ratio of 0.40. Median PFS was 7.3 months versus 3.5 months.
The safety profile differed from chemotherapy but serious adverse events remained common
Adverse events occurred in all patients assigned to daraxonrasib and in 97.7% of those assigned to chemotherapy. Grade 3 or higher adverse events occurred in 61.8% and 69.6%, respectively. Treatment-related adverse events caused treatment discontinuation in 1.2% of patients receiving daraxonrasib compared with 11.2% receiving chemotherapy.
The FDA lists rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage among the most common adverse reactions. The trial and approval therefore do not imply that daraxonrasib is a low-toxicity treatment. Its advantage is that it produced substantially longer survival while fewer patients stopped treatment because of treatment-related adverse events than in the chemotherapy group.
The result validates a target that resisted drug development for decades
RAS has been one of the central oncogenic drivers in cancer biology for decades, but its smooth protein surface and high affinity for guanosine triphosphate made it difficult to inhibit directly. Recent drug-development strategies have changed that. Daraxonrasib takes a broader approach than mutation-specific KRAS inhibitors by targeting the active state of multiple RAS variants.
Brian Wolpin, MD, MPH, who led the RASolute 302 study at Dana-Farber Cancer Institute, called the approval “a landmark advance for patients with metastatic pancreatic cancer.” The FDA’s Oncology Center of Excellence similarly described the trial results as “unprecedented” for an area with substantial unmet need.
The mechanism is distinct from immune checkpoint therapy, which removes inhibitory signals from immune cells, and from personalized mRNA cancer vaccines, which attempt to train the immune system against tumor-specific targets. Daraxonrasib instead directly interferes with a cancer-driving signaling protein inside tumor cells.
What the evidence cannot yet answer
RASolute 302 provides randomized evidence of a survival benefit, but several questions remain. The trial studied patients whose metastatic disease had already been treated, so it does not establish whether daraxonrasib should replace first-line multiagent chemotherapy in patients who can tolerate it. The study was open-label, although overall survival is an objective endpoint that is less vulnerable to assessment bias than symptom-based outcomes.
The enrolled population was also dominated by RAS G12 tumors. The overall-population results support the FDA’s biomarker-unrestricted indication, but the trial contained relatively few patients with G13, Q61, or no identified RAS mutation. More data will be needed to define the magnitude of benefit in those smaller molecular subgroups and to determine how resistance develops with longer use.
RASolute 302 was funded by Revolution Medicines, the manufacturer of daraxonrasib. Industry funding does not invalidate the randomized results, but it is relevant context when interpreting study design, analysis, and subsequent commercial claims.
Where daraxonrasib fits now
For eligible adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, daraxonrasib now offers an FDA-approved oral alternative to second-line chemotherapy with a substantial survival advantage demonstrated in a phase 3 trial. The approval also establishes RAS as a clinically actionable target across a broad group of pancreatic cancers rather than only a small molecular subset.
Wolpin’s framing is appropriately measured: the approval represents meaningful progress, not a cure. The next questions are whether earlier use can improve outcomes further, which combinations can delay resistance, and whether the same multiselective RAS strategy can produce similar gains in other RAS-driven cancers.
References
- O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. New England Journal of Medicine. 2026;395(4):325-337. DOI: 10.1056/NEJMoa2605555.
- U.S. Food and Drug Administration. FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer. August 26, 2026. FDA press announcement.